---
schema_version: "secwatch.filing_event.v1"
accession: "0001372299-25-000004"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:28:18.888770+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Ocugen presents clinical data with significant LLVA improvement (p=0.005) at Year 1 in retinal disease study

## Summary
- Mean change in LLVA from baseline improved in treated eye vs untreated (p=0.005 at Year 1).
- 75% of patients met responder criterion (6/8) at measured timepoints.
- Mean total atrophy area change at Month 12 showed trend favoring treated eye (p=0.055).
- Mean BCVA (ETDRS) change from baseline reported up to Month 12.
- Presentation includes Year 1 and Year 2 data from the clinical trial.

## SEC filing metadata
- accession: 0001372299-25-000004
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000137229925000004/0001372299-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000137229925000004/ocgn-20250616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372299-25-000004
- JSON: https://secwatch.observer/filing/0001372299-25-000004.json
- Plain text: https://secwatch.observer/filing/0001372299-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.